Navegando por Palavras-chave "Oclusão da veia retiniana"

Agora exibindo 1 - 2 de 2
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Oclusão de ramo venoso da retina associado ao uso de infliximabe: relato de caso
    (Conselho Brasileiro de Oftalmologia, 2011-06-01) Diniz, Bruno [UNIFESP]; Barbosa, Carolina Pelegrini [UNIFESP]; Regatieri, Caio Vinicius Saito [UNIFESP]; Rodrigues, Eduardo Buchele [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    A case of a 53 year-old female patient who developed branch retinal vein occlusion after six 3 mg/kg Infliximab infusions for rheumatoid arthritis treatment is reported. Hematological disorders, cardiopathy and chronic systemic hypertension evaluation were negative. The relationship between the infliximab therapy and the development of retinal vein occlusion raises awareness of the possibility of a potential side effect of this medication.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Thrombophilic mutations and risk of retinal vein occlusion
    (Conselho Brasileiro de Oftalmologia, 2007-12-01) Biancardi, Ana Luiza; Gadelha, Telma; Borges, Wander Inturias Sergillo; Moraes Jr., Haroldo Vieira De [UNIFESP]; Spector, Nelson; Universidade Federal do Rio de Janeiro; UFRJ Department of Internal Medicine Service of Hematology; Instituto Brasileiro de Oftalmologia; Universidade Federal de São Paulo (UNIFESP); Universidade Federal do Rio de Janeiro Department of Internal Medicine
    PURPOSE: The association of retinal vein occlusion and hereditary thrombophilia abnormalities is not established, with controversial results in the literature. This study investigates the association between retinal vein occlusion and three thrombophilic mutations: factor V 1691A (factor V Leiden), prothrombin 20210A (PT 20210A) and homozygous methylenetetrahydrofolate reductase 677T (MTHFR 677TT). METHODS: 55 consecutive retinal vein occlusion patients and 55 controls matched by age, gender and race, were tested for the presence of the following mutations: factor V Leiden, PT 20210A and MTHFR 677TT. The frequencies of the three mutations in cases and controls were compared. RESULTS: Factor V Leiden was found in 3.6% of patients and in 0% of controls; PT 20210A was found in 1.8% of patients and 3.6% of controls, (matched-pair odds ratio, 0.5; 95% confidence interval, 0.04 to 5.51); MTHFR 677TT was found in 9% of patients and 9% of controls (matched-pair odds ratio, 1; 95% confidence interval, 0.92 to 3.45). Arterial hypertension was more frequent in patients than controls (matched-pair odds ratio, 3.4; 95% confidence interval, 1.25 to 9.21). CONCLUSIONS: This study suggests that thrombophilic mutations are not risk factors for RVO. Routine investigation of hereditary thrombophilia in these patients is not justified.